The U.S. Food and Drug Administration granted vTv Therapeutics’ TTP399 Breakthrough Therapy designation for type 1 diabetes.
Abbott became the first anchor sponsor of the American Diabetes Association’s Health Equity Now platform to address health disparities for people with diabetes.
Almost 15,000 physicians, scientists, health-care professionals and industry representatives from around the globe presented research, treatment recommendations and advances toward a diabetes cure at the American Diabetes Association (ADA)’s 79th Scientific Sessions in San Francisco.
Insulin-dependent patients with T2D saw a significant drop in blood sugar levels after wearing Abbott’s continuous glucose monitoring system compared with those who use routine fingerstick testing.
A new study found that taking 4,000 international units per day may double the amount of vitamin D in the blood, but it gives most people roughly the same chance of developing blood sugar problems as people who do not take the vitamin.
Indianapolis-based Eli Lilly announced that the company’s Lispro Injection, an authorized generic version of the life-saving insulin Humalog, is available at pharmacies at a 50 percent lower list price.
Eli Lilly.’s top-selling diabetes drug Trulicity significantly reduced the risk of heart attack, stroke and heart-related death in a broad range of people with type 2 diabetes in a large clinical trial.
Novo Nordisk revealed that oral semaglutide achieved positive results in the PIONEER 5 study for the reduction of blood sugar levels and weight in adults with type 2 diabetes.
Two leading U.S. medical societies are poised to issue new diabetes treatment guidelines that are expected to reflect the lifesaving cardiovascular effects of Eli Lilly’s Jardiance.